Holen Sie sich die Stockscreener-App
6.57
1.94%
-0.13
Handel nachbörslich:
6.42
-0.15
-2.28%
Clene Inc Aktie (CLNN) Neueste Nachrichten
CLNN stock falls after Roth labels accelerated approval for ALS drug a 'long shot' - MSN
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Files Form 8-K with SEC Detailing Company Information and Common Stock Listing on NASDAQ - Minichart
Clene extends note maturity and amends stock plan following annual meeting - Investing.com
Clene Extends 2025 Convertible Notes to 2027, Defers $150,000 Monthly Payments - TradingView
Clene (NASDAQ: CLNN) extends convertible note maturity and adds 1M plan shares - Stock Titan
Clene (NASDAQ: CLNN) director granted 3,564 stock options at $6.81 exercise price - Stock Titan
Clene Inc. (NASDAQ: CLNN) director receives 3,658 stock options at $6.81 strike - Stock Titan
Clene (NASDAQ: CLNN) director awarded 4,361 stock options at $6.81 strike - Stock Titan
Clene Inc. (CLNN) director granted 5,159 stock options as equity compensation - Stock Titan
Clene (CLNN) director granted 4,291-share stock option package - Stock Titan
[Form 4] Clene Inc. Insider Trading Activity - Stock Titan
Clene (NASDAQ: CLNN) director Jonathon Gay receives 3,728 stock options at $6.81 - Stock Titan
Clene (CLNN) awards director two stock option grants at $6.81 - Stock Titan
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? - Yahoo Finance
CLNN News | CLENE INC (NASDAQ:CLNN) - ChartMill
Clene Inc. (CLNN) reports Q1 loss, misses revenue estimates - MSN
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Clene (CLNN) Gets a Buy from JonesTrading - The Globe and Mail
Is Clene (CLNN) Overvalued After Q1 2026? EPS -$0.69 Misses Est. - GuruFocus
JonesTrading Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Quick Look at Today's Ratings for Clene(CLNN.US), With a Forecast Between $30 to $50 - Moomoo
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Chidozie Ugwumba reports 9.7% stake in Clene Inc. (CLNN) - Stock Titan
Clene (CLNN) Receives Positive Analyst Rating and Funding Outloo - GuruFocus
Clene Inc. (NASDAQ: CLNN) insider reports 1.83M shares, 13% - Stock Titan
Clene Reports Q1 2026 Loss Amid Positive Regulatory News for CNM-Au8 - GuruFocus
Chidozie Ugwumba reports 1.92M Clene shares (NASDAQ: CLNN) 14.8% - Stock Titan
Clene Inc. 2026 Q1 Financial Results, Risk Factors, and Forward-Looking Statements – Quarterly Report Highlights - Minichart
Clene Releases Q1 2026 Financial Results - AlphaStreet
Clene (CLNN) Reports Q1 Revenue and Progress on ALS Treatment - GuruFocus
Clene Inc. Reports Q1 2026 Financial Results and Advances CNM-Au8 for ALS FDA Approval - Minichart
Clene 3Q Rev $15,000 >CLNN - Moomoo
Clene Expects to Submit NDA for CNM-Au8 Under the Accelerated Approval Pathway in 3Q >CLNN - Moomoo
Clene 3Q Loss/Shr 69c >CLNN - Moomoo
Clene Sees Operating Runway Into 4Q of 2026 - Moomoo
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights - Investing News Network
Clene IncEnters second amendment to senior secured convertible notesSEC filing - marketscreener.com
Clene Extends Debt Maturities and Strengthens Cash Runway - TipRanks
Clene (NASDAQ: CLNN) readies ALS NDA as Q1 loss deepens and cash runway extends - Stock Titan
Experimental ALS drug moves toward FDA filing as Clene shores up cash - Stock Titan
Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Clene Inc. (CLNN) posts larger Q1 2026 loss and flags going concern - Stock Titan
Clene Insider Sold Shares Worth $604,130, According to a Recent SEC Filing - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):